The quest for rejuvenation has gained new momentum, with biotech firms pouring billions into research. Companies like Life Biosciences and Altos Labs are betting big on cellular reprogramming, hoping to reverse age-related diseases and, perhaps, aging itself.

David Sinclair's team at Life Biosciences is already dosing their first volunteer in a treatment aimed at regenerating nerves, with broader applications potentially following. However, the field has seen many false dawns. From telomere lengthening to senolytic drugs, each new approach seems to eclipse the last.

Reprogramming cells by turning adult cells into stem cells is now in vogue, with promising mouse studies indicating improved tissue healing and cognitive function. Meanwhile, billions of dollars roll in, fuelling hopes and expectations. But do we have a magic bullet for aging, or are we chasing mirages once again?

The future is uncertain, but the excitement is palpable. Will reprogramming redefine what it means to grow old, or will it remain just another chapter in our ongoing battle with time? Stay tuned.